Low blood calcium in the context of "Denosumab"

Play Trivia Questions online!

or

Skip to study material about Low blood calcium in the context of "Denosumab"




⭐ Core Definition: Low blood calcium

Hypocalcemia is a medical condition characterized by low calcium levels in the blood serum. The normal range of blood calcium is typically between 2.1–2.6 mmol/L (8.8–10.7 mg/dL, 4.3–5.2 mEq/L), while levels less than 2.1 mmol/L are defined as hypocalcemic. Mildly low levels that develop slowly often have no symptoms. Otherwise symptoms may include numbness, muscle spasms, seizures, confusion, or in extreme cases cardiac arrest.

The most common cause for hypocalcemia is iatrogenic hypoparathyroidism. Other causes include other forms of hypoparathyroidism, vitamin D deficiency, kidney failure, pancreatitis, calcium channel blocker overdose, rhabdomyolysis, tumor lysis syndrome, and medications such as bisphosphonates or denosumab. Diagnosis should generally be confirmed by determining the corrected calcium or ionized calcium level. Specific changes may also be seen on an electrocardiogram (ECG).

↓ Menu

In this Dossier

Low blood calcium in the context of Calcium supplementation

Calcium supplements are salts of calcium used in a number of conditions. Supplementation is generally only required when there is not enough calcium in the diet. By mouth they are used to treat and prevent low blood calcium, osteoporosis, and rickets. By injection into a vein they are used for low blood calcium that is resulting in muscle spasms and for high blood potassium or magnesium toxicity.

Common side effects include constipation and nausea. When taken by mouth high blood calcium is uncommon. Calcium supplements, unlike calcium from dietary sources, appear to increase the risk of kidney stones. Adults generally require about a gram of calcium a day. Calcium is particularly important for bones, muscles, and nerves.

↑ Return to Menu

Low blood calcium in the context of Polystyrene sulfonate

Polystyrene sulfonates are a group of medications used to treat high blood potassium. Therapeutic effects generally appear hours to days after commencement of therapy. Common side effects include loss of appetite, gastrointestinal upset, constipation, and low blood calcium. Polystyrene sulfonates are given by mouth with a meal, or rectally by retention enema. Oral formulations often also contain the laxative sorbitol in order to lessen the risk of constipation which can be severe.

Polystyrene sulfonates are derived from polystyrene by the addition of sulfonate functional groups. Sodium polystyrene sulfonate was approved for medical use in the United States in 1958. A polystyrene sulfonate was developed in the 2000s to treat Clostridioides difficile associated diarrhea under the name Tolevamer, but it was never marketed.

↑ Return to Menu